Advancing the role of blood-based cancer screening tests and liquid biopsies in early cancer detection and precision oncology.
The Opportunity of Liquid Biopsies with Cancer Care
Cancer is the second leading cause of death worldwide, and 10 million deaths in 2020 were attributed to cancer. By 2050, the number of cancer cases is predicted to increase to 35 million based solely on projected population growth, according to the American Cancer Society.
Guardant Health was created in 2012 by co-Founders Helmy Eltoukhy and AmirAli Talasaz with the mission to conquer cancer with data. Since its founding, the company has transformed cancer care by providing critical insights into what drives the disease through its advanced blood and tissue tests, real-world data, and AI analytics. Guardant liquid biopsy tests help improve patient outcomes across all stages of cancer, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
Unlocking the Secrets of DNA in Precision Medicine
Guardant Health is the market leader in liquid Comprehensive Genomic Profiling (CGP) for all solid cancers, and is the only company to offer blood- and tissue-based tests across the entire continuum of cancer care: Shield for cancer screening; Guardant Reveal to detect minimal residual disease in early-stage cancer; and Guardant360 – Guardant360 CDx, and Guardant360 TissueNext for therapy selection in advanced cancer. Guardant Health has more than 10 years of data, more than 500k patient tests processed, and more than 170 biopharma partnerships.
Realizing the promise of precision medicine demands a comprehensive, multidimensional understanding of a patient’s tumor and immune response. Guardant Infinity is a unique multi-modal platform that can see the genomic and epigenomic profiles of cells, to characterize and quantify cancer. This technology is being used to detect cancer in blood with higher sensitivity than ever before and to provide a more complete view of cancer, powering multiple applications in precision oncology and enabling continuity from research to clinical practice. Guardant Health is updating its product suite to be on the Infinity platform.
The Future of Guardant Health
Guardant Health has an ambitious mission, but cannot do it alone. Through public-private partnerships, Guardant hopes to expand its reach globally to get tests to those who need them most, including internationally across Europe, Africa, Asia, the Middle East, and beyond. In addition, leveraging the Guardant Infinity platform, the team aims to expand the application of blood-based testing from screening for a single cancer to multi-cancers and eventually to multiple diseases.
Find out more about Global Health campaign
